Clinical Drug Investigation

, Volume 13, Issue 3, pp 152–161 | Cite as

Comparison of the Plasma, Urine and Blister Fluid Pharmacokinetics of Clarithromycin and Azithromycin in Normal Subjects

  • Guy W. Amsden
  • Charles H. Ballow
  • Alan Forrest


This open-label, multiple-dose study was intended to evaluate the pharmacokinetics of clarithromyin and azithromycin in plasma/serum, urine, and inflammatory and noninflammatory blister fluid, in 8 normal subjects. Co-modelling of the plasma/serum and urine data for each drug produced complex multicompartment models. Observed versus fitted drug concentration analyses evidenced a good fit of the data, despite moderate coefficient of variation values for all parameters. Blister fluid analyses demonstrated significant concentrating of both drugs in inflammatory versus noninflammatory conditions (areas under the blister fluid concentration versus time curves 31.6 versus 11.2 mg·h/L for clarithromycin and 2.88 versus 0.07 mg·h/L for azithromycin), although there was no significant difference in degree of accumulation between the agents. The results of this study are consistent with previous reports demonstrating white blood cell delivery of clarithromycin and azithromycin, and the concentrating of these agents in inflamed/infected areas.


White Blood Cell Count Clarithromycin Azithromycin Quality Control Sample Drug Invest 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Peters DH, Clissold SP. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutics potential. Drugs 1992; 44: 117–64PubMedCrossRefGoogle Scholar
  2. 2.
    Wollmer P, Pride NB, Rhodes CG, et al. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of position tomography. Lancet 1982; 2: 1361–4PubMedCrossRefGoogle Scholar
  3. 3.
    Kohna Y, Ohta K, Suwa T, et al. Autobacteriography studies of clarithromycin and erythromycin in mice. Antimicrob Agents Chemother 1990; 34: 562–7CrossRefGoogle Scholar
  4. 4.
    Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91 Suppl. 3A: 5S–11SPubMedCrossRefGoogle Scholar
  5. 5.
    Baldwin DR, Wise R, Andrews JM, et al. Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 1990; 3: 886–90PubMedGoogle Scholar
  6. 6.
    Fish DN, Gotfried MH, Danziger LH, et al. Penetration of clarithromycin into lung tissues from patients undergoing lung resection. Antimicrob Agents Chemother 1994; 38: 876–8PubMedCrossRefGoogle Scholar
  7. 7.
    Conte JE Jr, Golden JA, Duncan S, et al. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995; 39: 334–8PubMedCrossRefGoogle Scholar
  8. 8.
    Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990; 25 Suppl A: 73–82PubMedGoogle Scholar
  9. 9.
    Ballow CH, Amsden GW, Forrest A, et al. Pharmacokinetics (Pks) of azithromycin in serum urine, inflammatory (IB) and non-inflammatory (NB) blisters [abstract]. Clin Pharmacol Ther 1993; 53: 211Google Scholar
  10. 10.
    Ballow CH, Amsden GW, Higher VS, et al. Concentration of azithromycin (A) in polymorphonuclear leukocytes (PMNs): role in tissue delivery [abstract 3274]. Presented at the 19th International Conference on Chemotherapy, Montreal, Quebec, Canada, 1995Google Scholar
  11. 11.
    D’Argenio DZ, Schumitzky A. ADAPTII users guide. Biomedical simulations resource. University of Southern California, Los Angeles, California, 1992Google Scholar
  12. 12.
    D’Argenio DZ, Schumitsky A. A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Prog Biomed 1979; 9: 115–34CrossRefGoogle Scholar
  13. 13.
    Yamaoka K, Terumichi N, Uno T. Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6 165–75PubMedGoogle Scholar
  14. 14.
    Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995: 492–528Google Scholar
  15. 15.
    Ballow CH, Amsden GW, Forrest A, et al. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin (C) and azithromycin (A) in normal subjects. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, Florida, 1994Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Guy W. Amsden
    • 1
  • Charles H. Ballow
    • 2
  • Alan Forrest
    • 2
  1. 1.The Clinical Pharmacology Research Center and Departments of Pharmacy and MedicineBassett HealthcareCooperstownUSA
  2. 2.The Clinical Pharmacokinetics LaboratoryMillard Fillmore HospitalBuffaloUSA

Personalised recommendations